Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT04637048 Enrolling by invitation - Colorectal Cancer Clinical Trials

Observational Study on Patients With Hepatobiliary Tumors

Start date: February 16, 2017
Phase:
Study type: Observational

Hepatobiliary tumors have a poor prognosis and high individual heterogeneity, the patient with hepatobiliary tumors even accepted radical surgery, the postoperative recurrence rate is still high. Therefore, it is of great significance to find important prognostic markers to improve patient prognosis and formulate new treatment plans. In recent years, targeted therapy and immunotherapy make cancer treatment enter a new field, However, tumor heterogeneity is the greatest challenge in cancer therapeutics and biomarkers discovery. In this study, we collected a wide rang of patients' information, including photos of patients' face, physical strength and nutrition indicators, blood ,stool and pathological tissue specimens from tumor patients, then Multi-omics testing were applied to Looking for novel therapeutic targets and prognostic markers to predict patient response to treatment. Clinicians choose the best treatment plan for the patient based on the test results to improve the patient's survival time and quality of life.

NCT ID: NCT04635527 Terminated - Clinical trials for Hepatocellular Carcinoma

A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma

Start date: December 24, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this phase Ib study is to assess the safety, tolerability and effectiveness of IBI318 in combination with conventional TACE (cTACE) in patients with potentially resected hepatocellular carcinoma.

NCT ID: NCT04634357 Recruiting - Liver Cancer Clinical Trials

ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma

ARYA-2
Start date: July 19, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.

NCT ID: NCT04627363 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm clinical study to preliminarily observe and evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin synchronous combined with Bevacizumab and Toripalimab as the first-line therapy for advanced HCC.

NCT ID: NCT04627012 Completed - Clinical trials for Hepatocellular Carcinoma

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Start date: January 1, 2018
Phase:
Study type: Observational

For the advanced hepatocellular carcinoma (HCC), the targeted therapy and immunotherapy are recommended. This study focused on the management of Lenvatinib combined anti-PD1 antibody for the HCC. This study will create a database that will provide clinical parameters and outcomes of patients undergoing Lenvatinib and anti-PD1 antibody as part of their standard of care in hopes of answering key clinical questions.

NCT ID: NCT04620538 Recruiting - Clinical trials for Hepatocellular Carcinoma

Volatile Organic Compounds for the Assessment of Liver Disease

VOCAL
Start date: April 1, 2021
Phase:
Study type: Observational

This study aims to determine whether a breath test could be used for early detection of hepatic fibrosis, cirrhosis or hepatocellular carcinoma. Patients who are attending for a planned liver outpatient services or investigations will be approached to provide a breath sample. Multi platform mass spectrometry analysis will be performed to establish volatile biomarkers that can discriminate between fibrosis, cirrhosis and hepatocellular carcinoma.

NCT ID: NCT04619342 Recruiting - Clinical trials for Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)

Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)

Start date: October 30, 2020
Phase: N/A
Study type: Interventional

A Single center, Open, Randomized Controlled Trial Evaluating the Safety and Efficacy of GSMs-TACE Combined with Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) with Type III Portal Vein Tumor Thrombus (PVTT).

NCT ID: NCT04619329 Recruiting - Clinical trials for Huge Hepatocellular Carcinoma (HCC) (=10cm)

Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in Treatment of Huge Hepatocellular Carcinoma (HCC) (≥10cm)

Start date: October 30, 2020
Phase: N/A
Study type: Interventional

A Single center, Open, Randomized Controlled Trial Evaluating the Safety and Efficacy of GSMs-TACE combined with Surgical Resection in Treatment of Huge Hepatocellular Carcinoma (HCC) (≥10cm).

NCT ID: NCT04618367 Completed - Clinical trials for Carcinoma, Hepatocellular

HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

This study intends to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and Sintilimab for patients hepatocellular carcinoma and portal vein tumor thrombus.

NCT ID: NCT04615143 Recruiting - Clinical trials for Recurrent Hepatocellular Carcinoma

Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC

TALENT
Start date: December 1, 2020
Phase: Phase 2
Study type: Interventional

This non-randomized phase II clinical trial aimed to explore the efficacy and safety of Tislelizumab or Tislelizumab combined with Lenvatinib as neoadjuvant treatment for resectable RHCC patients